Skip to main content
. 2020 Aug 12;9(8):2615. doi: 10.3390/jcm9082615

Table 2.

Fatty acid composition of phospholipids in visceral adipose tissue from non-obese patients and morbid obese patients.

Fatty Acid Non-Obese MO-Low-IR MO-High-IR MO-Metf-TDM2
Lauric acid 12:0 0.58 ± 0.48 0.11 ± 0.17 0.25 ± 0.38 0.26 ± 0.24
Myristic acid 14:0 1.44 ± 0.29 2.18 ± 1.78 1.28 ± 0.92 1.40 ± 1.10
Palmitic acid 16:0 22.772.8 22.2 ± 1.9 22.9 ± 3.1 21.7 ± 1.5
Palmitoleic acid 16:1n-7 2.63 ± 0.81 2.92 ± 1.07 3.01 ± 0.82 2.41 ± 0.49
Stearic acid 18:0 15.8 ± 3.9 12.2 ± 2.0 a 12.8 ± 2.2 12.8 ± 1.2
Oleic acid 18:1n-9 30.4 ± 4.8 28.2 ± 3.5 27.9 ± 4.6 26.5 ± 5.5
Vaccenic acid 18:1n-7 0.94 ± 1.33 2.62 ± 0.55 a 2.35 ± 1.38 a 2.10 ± 1.04
Linoleic acid 18:2n-6 16.1 ± 4.5 17.8 ± 2.0 14.7 ± 3.5 16.4 ± 3.0
Gamma-linolenic acid 18:3n-6 0.03 ± 0.08 0.02 ± 0.06 0.07 ± 0.27 0.01 ± 0.01
α-Linoleic acid 18:3n-3 0.29 ± 0.32 0.54 ± 0.84 0.28 ± 0.38 0.55 ± 0.54
Eicosanoic acid 20:0 1.01 ± 0.50 0.54 ± 0.54 1.09 ± 1.06 1.29 ± 0.51
Gondoic acid 20:1n-9 0.80 ± 0.61 0.89 ± 0.34 1.12 ± 1.79 1.13 ± 0.58
Eicosadienoic acid 20:2n-6 0.47 ± 0.51 0.73 ± 0.59 0.62 ± 1.06 0.87 ± 0.60
Dihomo-gamma-linolenic acid 20:3n-6 0.73 ± 0.34 1.17 ± 0.57 1.32 ± 1.33 1.79 ± 0.86
Arachidonic acid 20:4n-6 4.18 ± 1.48 5.62 ± 1.39 6.33 ± 1.99 a 7.24 ± 2.28 a
Eicosatrienoic acid 20:3n-3 0.05 ± 0.09 0.14 ± 0.28 0.33 ± 0.24 0.18 ± 0.20
Eicosapentaenoic acid 20:5n-3 0.35 ± 0.29 0.27 ± 0.32 0.50 ± 0.63 1.04 ± 1.49
Adrenic acid 22:4n-6 0.37 ± 0.35 0.72 ± 0.55 1.01 ± 1.03 0.68 ± 0.47
Docosapentaenoic acid 22:5n-3 0.24 ± 0.27 0.23 ± 0.35 0.65 ± 0.86 0.49 ± 0.48
Docosahexaenoic acid 22:6n-3 0.61 ± 0.98 0.80 ± 0.64 0.77 ± 1.01 1.08 ± 0.74
Total saturated fatty acids 41.6 ± 5.9 37.2 ± 3.7 38.9 ± 5.0 37.4 ± 2.3
Total monounsaturated fatty acids 34.7 ± 4.8 34.6 ± 4.0 34.4 ± 5.1 32.2 ± 5.5
n-3 polyunsaturated fatty acids 1.54 ± 1.45 1.99 ± 1.28 2.54 ± 2.34 3.35 ± 3.11
n-6 polyunsaturated fatty acids 22.0 ± 5.1 26.0 ± 2.1 24.1 ± 4.9 26.9 ± 3.7

Results are represented as mean ± SD. a p < 0.05 significant differences with regard to the non-obese patients.